WO2003102213A2 - Mutants de polymerase i d'adn sujet a l'erreur et techniques de mutagenese aleatoire ciblee en culture continue utilisant ces mutants de polymerase i d'adn sujet a l'erreur - Google Patents

Mutants de polymerase i d'adn sujet a l'erreur et techniques de mutagenese aleatoire ciblee en culture continue utilisant ces mutants de polymerase i d'adn sujet a l'erreur Download PDF

Info

Publication number
WO2003102213A2
WO2003102213A2 PCT/US2003/016798 US0316798W WO03102213A2 WO 2003102213 A2 WO2003102213 A2 WO 2003102213A2 US 0316798 W US0316798 W US 0316798W WO 03102213 A2 WO03102213 A2 WO 03102213A2
Authority
WO
WIPO (PCT)
Prior art keywords
dna polymerase
mutant
motif
pol
mutagenesis
Prior art date
Application number
PCT/US2003/016798
Other languages
English (en)
Other versions
WO2003102213A3 (fr
Inventor
Manuel Camps
Lawrence A. Loeb
Original Assignee
University Of Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Washington filed Critical University Of Washington
Priority to EP03736735A priority Critical patent/EP1504091A4/fr
Priority to AU2003237269A priority patent/AU2003237269A1/en
Priority to JP2004510449A priority patent/JP2005528114A/ja
Priority to CA002485203A priority patent/CA2485203A1/fr
Publication of WO2003102213A2 publication Critical patent/WO2003102213A2/fr
Publication of WO2003102213A3 publication Critical patent/WO2003102213A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C12N15/1024—In vivo mutagenesis using high mutation rate "mutator" host strains by inserting genetic material, e.g. encoding an error prone polymerase, disrupting a gene for mismatch repair
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C12N9/1252—DNA-directed DNA polymerase (2.7.7.7), i.e. DNA replicase

Definitions

  • This invention relates to mutants of DNA polymerase I and methods for their application, particularly to DNA Pol I mutants engineered to have decreased fidelity of replication and to methods for their application in random mutagenesis for the modification of target sequences in continuous culture.
  • Enzymes are routinely used in the pharmaceutical and biotechnology industries, and are finding increasing applications as biocatalysts in chemical synthesis and bioremediation. Native enzymes seldom possess the properties required for direct industrial or medical application, because they have evolved to perform specific functions within specific biochemical environments generally different from the chemical environments of industrial and medical applications.
  • Two general approaches have been used to alter enzyme performance. One involves the replacement of individual amino-acid residues based on detailed structural information, and the other involves the production of large libraries of randomly substituted variants, or mutants.
  • mutagenesis followed by the identification of mutants with properties of interest allows for fine-tuning enzyme performance with respect to optimal conditions for catalysis and/or substrate specificity. This approach has great potential in improving complex biosynthetic and degradative pathways, and in overcoming the rate-limiting steps for medical and industrial applications.
  • random mutagenesis requires no prior knowledge of the structure of the targeted enzyme or of the mechanistic aspects of the reaction.
  • the main limitation of random mutagenesis is that only a small fraction of the sequence space can be effectively explored. This is due to the astronomical number of possible combinations of amino acid substitutions in an average enzyme (far exceeding the size of most libraries) and to the frequent generation of functionally deficient mutants.
  • the diversity of random mutant libraries is also constrained by the error-correcting nature of the genetic code.
  • a particular amino-acid residue within a protein may be replaced by one of 19 other, naturally occurring amino acids, a given single point mutation within the codon that encodes the particular amino acid results in an average of only 6 different amino-acid substitutions, and these substitutions tend to be conservative, resulting in replacement of the particular amino acid with another amino acid having similar physicochemical properties.
  • Finding the desired variants is usually a major challenge. This may be done either by true selection or by screening.
  • True selection consists of giving a growth advantage to the clones that show the desired activity, and is therefore performed in vivo.
  • selection-based techniques can be extremely effective for increasing the representation of desired variants in populations.
  • Selection-based techniques have the added advantage of eliminating defective and inactive mutants.
  • selection-based techniques are not available for all enzymes and desired properties.
  • desired variants can be identified by screening. Screening is more versatile than selection-based techniques, because screening does not require biological activity. However, screening is more limited in throughput.
  • in vivo mutagenesis offers significant advantages over in vitro methods, because in vivo mutagenesis may be readily coupled to a positive genetic selection. This promotes the accumulation of beneficial mutations, a strategy known as "directed evolution".
  • directed evolution By the stepwise selection of mutations with a positive effect on the phenotype of interest, we can reach combinations of mutations that had a very low probability at the beginning of the experiment.
  • This iterative process of mutagenesis and selection is greatly facilitated by performing both mutagenesis and selection simultaneously in vivo.
  • the efficacy of a given in vivo mutagenesis system relies predominantly on the type of cellular hosts or "mutator strains" used, and the currently available mutator strains are inadequate for a number of reasons.
  • mutD5 is a mutant of Pol III deficient in proofreading activity [Scheuermann, R. H. and Echols, H., Proc. Natl. Acad. Sci. U S A 81: 7747-51 (1984)].
  • errors introduced by this polymerase, the main replicative polymerase in E. coli result in the saturation of mismatch repair and a dramatic increase in mutagenesis [Schaaper, R. M. and Radman, M., Embo. J. 8: 351 1-16 (1989)].
  • Other strains are based on mismatch repair inactivation [Glickman, B. W. and Radman, M., Proc. Natl. Acad. Sci.
  • mutator strains exist, but have the following limitations with respect to enzyme modification by random mutagenesis: (1) the dependence on specific defects in DNA polymerases and/or in DNA repair pathways of a host; (2) the unhealthy state of host cells resulting from widespread chromosomal mutagenesis and from defective DNA repair pathways; (3) the increase in phenotypic noise resulting from non-specific chromosomal mutations that makes selection based on phenotypic properties less reliable; and (4) the progressive decrease in mutagenesis rates that occurs with prolonged culture.
  • random mutagenesis in culture. Specifically, healthier host strains and independence from a specific genetic background are desired.
  • One embodiment of the present invention relates to the engineering of error- prone DNA polymerases within the Pol I family and methods for their use in implementing random mutagenesis of exogenous target genes of interest in continuous culture at frequencies that exceed those of chromosomal DNA.
  • Various embodiments of the present invention relate to the engineering of DNA polymerases by introducing mutations in residues within their active sites that increase the error rates of the polymerases, collectively called "error-prone Pol I mutants". These mutations involve either motif A, or motif B, or both motifs A and B.
  • compositions of various embodiments of the present invention comprise the DNA sequences encoding any portion of the engineered sites of Pol I mutants having low- fidelity, any portion of the Pol I mutants containing the engineered sites conferring low-fidelity, and host strains comprising either the DNA or polypeptide sequences representing these error-prone Pol I mutants.
  • compositions and methods relate to a method of expressing these error-prone polymerase mutants under carefully regulated, or "optimized", culture conditions to achieve an elevated frequency of mutagenesis preferentially targeted to an exogenously-introduced plasmid encoding a sequence of interest.
  • the compositions and methods provide for random mutagenesis performed in continuous culture, without plasmid recovery between selection steps, which greatly facilitates the accumulation of beneficial mutations.
  • the compositions and methods can be easily adapted for use in any existing strain suitable for complementation with the target gene because the critical reagents are encoded in transformable vectors, and mutagenesis is not contingent on any specific genetic defect in the host strain.
  • Suitable strains include cells endogenously expressing wild-type DNA polymerase and/or wild type DNA repair function.
  • the compositions and methods can introduce a broad spectrum of mutations in any DNA target sequence, prokaryotic or eukaryotic, resulting in the identification of sequences encoding polypeptides with altered properties.
  • FIGS. 1 A-B provide a general overview of the 2-plasmid mutagenesis system, involving the co-expression of an error-prone Pol I and an exogenously introduced DNA template.
  • FIG. 2 illustrates residues within motif A and motif B in the active site of E. coli DNA polymerase that are critical for the fidelity of replication during nucleotide incorporation.
  • FIG. 3A illustrates embodiments of template DNA, including prokaryotic and eukaryotic DNA, to be targeted for in vivo mutagenesis by error-prone Pol I.
  • FIG. 3B illustrates, in particular, several target plasmids having variable distances between the origin of replication (ori) and the ochre stop codon within the ⁇ -lactamase gene used as a reporter for mutagenesis.
  • FIG. 4 illustrates the chemical structure of three classes of ⁇ -lactamase substrates: penicillin, cephalosporin, and aztreonam.
  • Aztreonam served as a selective agent in Example 7.
  • FIG. 5A illustrates the initial conditions and a method for inducing mutagenesis in culture by the expression of error-prone Pol I in the presence of a target plasmid, as discussed in Example 2.
  • FIG. 5B illustrates the optimized conditions and a method for inducing mutagenesis in culture by the expression of error-prone Pol I in the presence of a target plasmid, as discussed in Example 2.
  • FIG. 6 illustrates the effect of culture conditions on mutagenesis by the expression of error-prone Pol I mutants, as discussed in Example 3.
  • FIG. 7 illustrates the copy number of the target plasmid when D424A I709N
  • A759R error-prone Pol I is expressed under optimized conditions.
  • FIG. 8A shows the location of mutations identified within a 650 bp interval beginning at a distance of lOObp from the ColEl origin of replication (ori), as discussed in Example 5.
  • FIG. 8B shows how distance affects the frequency of mutations in a target plasmid, as discussed in Example 5.
  • FIG. 9 illustrates the effect of error-prone Pol I expression on plasmid mutagenesis rates in a host that is wild type for Pol I and proficient in major pathways of DNA repair, as discussed in Example 6.
  • FIG. 10 shows dose-response curves of aztreonam resistance conferred by a representative subset of mutations identified following selection with aztreonam, as discussed in Example 7. DETAILED DESCRIPTION OF THE INVENTION
  • Embodiments of the present invention are directed to a generation of Pol I mutants, collectively referred to as "error-prone Pol I mutants," that have been altered from the wild-type DNA polymerase at specific residues that form the active domain, resulting in increased misincorporation by these Pol I mutants during catalysis.
  • error-prone Pol I mutants are potentially useful in any industry that employs enzymes to perform a biochemical reaction, where any improvement in the activity of such enzymes is desirable.
  • Embodiments of the present invention are useful for broad applications in the pharmaceutical/medical industry as well as any industry that engages in a process that is enzyme-dependent.
  • FIG. 1A provides an overview of the random mutagenesis approach in continuous culture mediated by error-prone Pol I mutants.
  • a prokaryotic host cell containing a first vector encoding a target gene of interest and a second vector encoding an error-prone Pol I mutant is represented.
  • a suitable host cell may or may not express the wild type Pol I endogenously.
  • FIG. IB illustrates an example of how the expression of low-fidelity Pol I mutants in host cells promote plasmid-specific mutagenesis, without substantially modifying the chromosome of a prokaryotic host when expressed in vivo.
  • a host cell that has wild type Pol III (the major DNA polymerase) and temperature- sensitive Pol I activities can be transformed with two plasmids.
  • mutagenesis occurs at a restrictive temperature
  • the endogenous temperature-sensitive Pol I can be inactivated.
  • a target gene of interest can be inserted downstream of a ColEl origin of replication ("ori"), which is specifically recognized by Pol I.
  • ori ColEl origin of replication
  • a second plasmid (“pSClOl ori”) can express a mutant DNA polymerase that is engineered within the active site to erroneously replicate substrate DNA, such as the first plasmid containing the target gene. Since DNA synthesis by Pol I is very limited in the chromosome, mutagenesis is largely restricted to the target plasmid upon expression of the error-prone Pol I mutants in vivo.
  • compositions relating to the mutagenesis system cover two general embodiments of the invention, the compositions relating to the mutagenesis system, and the methods for using the present compositions for implementing directed evolution by continuous culture in vivo.
  • compositional embodiments directed to error-prone Pol I mutants the following provides descriptions of: (1) the development and characterization of motif A and/or B Pol I mutants, (2) the host strains that can be used to express motif A and/or B Pol I mutants, and (3) the types of target sequences that can be used by the motif A and/or B Pol I mutants. Specific Examples relating to these compositions are referenced and provided in the following section.
  • Type I polymerases consist of a single polypeptide with 3 distinct domains [Kornberg, A. and Baker, T. A., DNA replication, second edition, Vol. 1, p. 931. New York: W.H. Freeman and Company (1992)].
  • 3 residues (1614, A661 , and T664) that are critical for fidelity in one such polymerase, Thermus aquaticus (Taq) polymerase were previously identified by the present inventors [Suzuki et al., J. Biol. Chem. 272: 1 1228-35 (1997); Patel et al., J. Biol. Chem. 276: 5044-51 (2001)].
  • motifs A and B create a pocket in the catalytic site that accommodates an incoming nucleotide. Certain amino acid substitutions at specific positions in these motifs favor misincorporations, due to an enlargement of the active site cavity and/or to a more stable "closed” conformation [Suzuki et al., J. Biol. Chem. 272: 11228-35 (1997); Patel et al., J. Biol. Chem. 276: 5044-51 (2001)].
  • compositions relating to variants of E. coli DNA polymerases i.e., error-prone Pol I mutants, that are engineered within the active site, particularly in motif A and/or motif B, to produce an elevated frequency of replication mistakes within substate DNA.
  • FIG. 2 illustrates the positions within motifs A and B that are identified and characterized by the invention, which are critical for the fidelity of E. coli polymerases. In particular, position 1709 of motif A and positions S756 and A759 of motif B of E. coli DNA Pol I are engineered to increase incorporation of mismatched residues. These mutants are further described in the following sections. Methods for the construction of error- prone Pol I mutants are provided below in Example 1.
  • One embodiment is directed to E. coli error-prone Pol I mutants bearing amino-acid substitutions in both the motif A and 3' -» 5' exonuclease domains, which exhibit an elevated frequency of misinco ⁇ oration during replication of target DNA.
  • Motif A mutants were altered by substituting wild type aspartic acid (D) at position 424 with alanine (A) to inactivate the exonuclease function essential for proofreading.
  • D wild type aspartic acid
  • A alanine
  • Another embodiment is directed to E. coli error-prone Pol I mutants, bearing mutations in both the motif B and the 3' - 5' exonuclease domains, that produce an elevated frequency of misinco ⁇ oration during replication of target DNA.
  • Motif B mutants were altered by substituting wild type aspartic acid (D) at position 424 with alanine (A) to inactivate the exonuclease function essential for proof-reading.
  • motif B mutants lacking exonuclease activity, that include the D424A S756E and D424A A759R mutants, in which the wild type serine (S) in position 756 is substituted with glutamic acid (E) and the wild type alanine (A) in position 759 is substituted with arginine (R).
  • S serine
  • E glutamic acid
  • A wild type alanine
  • R arginine
  • a further embodiment is directed to E. coli error-prone Pol I mutants, bearing amino-acid substitutions in both motif A and motif B, that produce highly elevated frequencies of misinco ⁇ oration during replication of target DNA.
  • These motifs A and B mutants were altered to inactivate their 3'- 5' exonuclease activity by substituting wild type aspartic acid (D) at position 424 with alanine (A), although this modification doesn't appear to have a significant impact on mutagenesis in these mutants (see Table 2).
  • FIG. 2 provides examples of error-prone Pol I mutants carrying amino-acid substitutions in motif A and motif B.
  • D424A I709N A759R One such mutant is the "D424A I709N A759R,” in which the wild type isoleucine (I) at position 709 is substituted with an asparagine (N) and the wild type alanine (A) in position 759 is substituted with arginine (R).
  • Another mutant in both motifs is referred to as the "D424A I709F A759R,” in which the wild type isoleucine (I) at position 709 is substituted with a phenylalanine (F) and the wild type alanine (A) in position 759 is substituted with arginine (R).
  • These error-prone Pol I mutants bearing a single or more amino-acid substitution in each motif A and motif B of the active site, may be used in vitro and in vivo.
  • Additional embodiments related to the above-discussed E.coli error-prone Pol I mutants carrying motif A, motif B, and the combination of motif A and motif B mutations, include homologous mutations that may be engineered into other members of the Pol I family of DNA polymerases, including the DNA polymerase of Staphylococcus aureus, Streptococcus pneumoniae, Bacillus subtillis, or Salmonella enteritidis.
  • Suitable hosts for the expression of mutant motif A and/or motif B Pol I genes are not restricted to strains with inactivated DNA repair mechanisms or to strains with defective chromosomal Pol ⁇ .
  • the mutagenesis system is therefore uniquely adaptable to a variety of strains imaginable.
  • Various embodiments that employ cells with or without endogenous wild type Pol I activity may be used to express mutators.
  • Other embodiments are directed to strains with or without inactivated DNA repair mechanisms.
  • Examples of host strains that may provide the appropriate cellular environment for supporting mutagenesis mediated by error-prone Pol I expression include E. coli strains such as the JS200 and XL1 -Blue.
  • the JS200 strain represents a strain having a temperature-sensitive allele of Pol I (polA12) in the chromosome [Monk, M. and Kinross, J., J. Bacteriol. 109: 971-78 (1972)].
  • the XLl-Blue strain represents a strain having endogenous wild type Pol I activity and substantial proficiency in DNA repair, and therefore able to support the co-expression of exogenous error-prone Pol I mutants.
  • Another embodiment is directed to a number of existing strains that are deficient in specific enzymes that can be functionally complemented, permitting the exploitation of the system to its fullest extent.
  • the error-prone Pol I mutants encoding either motif A and/or motif B amino-acid substitutions can be delivered into a prokaryotic host as part of a circular vector such as a plasmid or in a linear form, such as in a bacterial phage.
  • the vehicle encoding the motif A and/or motif B Pol I can remain in an unintegrated form, as an exogenous plasmid for example.
  • single or multiple copies of genes encoding any portion of motif A and/or motif B mutator sequences may be integrated into the chromosome of the prokaryotic host, generating stable lines of mutator prokaryotic strains or cell lines.
  • a double-stranded DNA fragment consisting of 3000 bp of the PolAl locus encoding a low-fidelity mutant that is flanked on the 5' and 3' sides by approximately 1000 bp of the native genomic sequence can be subcloned into a plasmid with a temperature- sensitive origin of replication.
  • Chloramphenicol can be used as a marker for positive selection and sucrose can be used for negative selection.
  • the resulting plasmid can be used to transform JS200 cells and can be selected for chloramphenicol resistance under permissive conditions at 30°C.
  • the culture can be switched to 37°C in order to block plasmid replication by the temperature-sensitive Pol I allele.
  • These conditions confer a dramatic growth advantage to cells that have integrated the error- prone Pol I mutants in their chromosome, such that most of the colonies that grow at 37°C are expected to be stable integrants that can be confirmed by PCR.
  • sucrose can be added in the selection step to actively select against the presence of the plasmid.
  • a number of other methods for generating allelic substitutions that are currently practiced by those skilled in the art are contemplated.
  • the in vivo mutagenesis system contemplates a plurality of suitable templates, as diagrammed in FIG. 3.
  • the targeted template can be a prokaryotic gene (FIG. 3A) encoding a full-length protein or any fragments thereof.
  • the targeted template can be a eukaryotic gene (FIG. 3A) that may be in the form of a cDNA or genomic DNA without introns, or any fragments thereof.
  • an eukaryotic gene in any of these forms may be exogenously introduced and unfaithfully replicated in prokaryotic strains that express endogenously temperature-sensitive or wild type Pol I.
  • a library of mutated eukaryotic DNA may be isolated from their prokaryotic hosts by using, for example, conventional methods for plasmid preparation or for phage recovery.
  • the plasmid library Once the plasmid library is isolated, it may be subjected to restriction-enzymatic digestion with one or more endonucleases that are commercially available to once skilled in the art of molecular biology to dissociate the targeted gene of interest from the vector. This can be easily done using gel electrophoresis to separate DNA fragments based on shape and size differences.
  • the gene library may be used for subcloning into eukaryotic expression vectors.
  • the mutated versions of the target gene of interest may be transformed into eukaryotic cells or conventional cell- lines to screen for a desired property or function.
  • Other procedures for manipulating DNA that are within the scope of a person skilled in the art are also contemplated.
  • the ⁇ 2913recA strain which is defective in thymidine synthase ( ⁇ thyA572), may be co-transformed with a vector encoding the human TS cDNA placed downstream from ori and a vector expressing an error-prone Pol I mutant. Selection may be conducted in increasing concentrations of 5-flourouracyl ("5FU"), a potent inhibitor of thymidine synthase. Clones having increased resistance to 5FU can be isolated and their mutations characterized using materials and methods practiced by persons skilled in the art [Landis et al., Cancer Res. 61 : 666-72 (2000)].
  • 5FU 5-flourouracyl
  • the template that is subjected to in vivo mutagenesis by Pol I mutators may be delivered in a circular form, such as a plasmid, or in a linear form.
  • the template may be delivered by a bacteriophage that can inject phage genomic material into a prokaryotic host expressing one error-prone Pol I mutant.
  • bacteriophage depends on Pol I for replication, like for example, bacteriophage T4 in a RNAseH-deficient background [Hobbs, L.S. and Nossal, N.G. J. Bacteriol 178: 6772-6777 (1996)]
  • viral replication in the host results in expansion and mutagenesis of the template, generating a library of mutants.
  • the targeted gene(s) can be exogenously introduced in a Pol I-dependent plasmid, including the plasmids ColEl, pBR322, pl5A, pMB, pNT7, pVH51, RSF1030, CloDF13, ColE2, pLMV158, pLSl, and their derivatives.
  • the target plasmid is distinct from the plasmid encoding the error-prone Pol I mutant, which is Pol I-independent.
  • the system comprises one plasmid encoding an error-prone Pol I mutant and another plasmid or phage encoding the targeted gene.
  • Other methods of gene delivery that are known and practiced by persons skilled in the art are included in these embodiments.
  • an ochre stop codon replaces glutamic acid (GAA) 26 codons downstream from the translation start of the TEM-1 ⁇ -lactamase gene.
  • GAA glutamic acid
  • the ochre stop codon is positioned approximately 230 bp downstream of the ori. Because most mutations within the ochre stop codon result in its reversion to a codon encoding an amino acid and thus allow for ⁇ -lactamase expression, mutations can be scored as carbenicillin- resistant colonies.
  • the ⁇ -lactamase gene can be subjected to in vivo mutagenesis in the presence of increasing concentrations of aztreonam, to select mutations that improve the ⁇ - lactamase substrate recognition of aztreonam.
  • the TEM-1 isoform of ⁇ -lactamase is the most frequently occurring ⁇ -lactamase found in Gram-negative clinical isolates, functioning in the catalytic degradation of ⁇ -lactams by amide-bond hydrolysis [Wiedemann et al., J. Antimicrob. Chemother. 24 Suppl. B: 1-22 (1989)].
  • the catalytic efficiency of ⁇ -lactamase varies greatly depending on the ⁇ -lactam used as a substrate.
  • Extended-spectrum antibiotics include aztreonam and third-generation cephalosporins, such as cefotaxime and ceftazidime, that carry bulky adducts specifically designed to minimize recognition by ⁇ -lactamase.
  • FIG. 4 illustrates the structure of representatives of each of these ⁇ -lactam substrates including penicillin, cephalosporin, and aztreonam. Aztreonam was used as a selective agent in Examples 4 and 7.
  • Mutations belonging to the second group that include the E104K (glutamic acid to lysine) and the M182T (methionine to threonine), are typically positioned distantly from the active site. They are most likely selected in response to mutations in the catalytic site to suppress destabilizing effects resulting from these mutations [Petrosino J. et al., Trends Microbiol. 8: 323-327 (1998)]. Mutagenesis of the ⁇ -lactamase gene coupled with aztreonam selection was chosen to validate the use of error-prone Pol I random mutagenesis for enzyme modification.
  • Mutants in Combination with Selection or Screening
  • the following provides descriptions of: (1) the advantages and applications of error-prone Pol I-mediated mutagenesis in continuous culture, and (2) the parameters of the optimized culture conditions.
  • a method of random mutagenesis, followed by selection or screening allows the simultaneous exploration of sequence, structure, and functional space of an enzyme without any detailed mechanistic or structural information [Skandalis et al., Chem. Biol. 4: 889-98 (1997)]. Mutagenesis and selection/screening may be repeated in an iterative fashion so that the sequence space is directed toward changes that improve performance, in an approach referred to as "directed evolution.” Performing mutagenesis and selection simultaneously in continuous culture eliminates the need for recovering target DNA between selection steps.
  • Directed evolution still explores only a small fraction of the sequence space, so it is unlikely to achieve optimal solutions or to evolve new catalytic functions.
  • Larger leaps in sequence can be achieved by shuffling sequences within a library of mutants that has been prescreened for activity or within a family of enzymes [Smith, G. P., Nature. 370: 324-5 (1994); Crameri, A. et al., Nature. 391 : 288-91 (1998)].
  • the invention can also be used in combination with these shuffling technologies.
  • the error-prone DNA Pol I mutants may produce additional mutations during these processes of shuffling in vitro and in vivo.
  • the error-prone DNA polymerases of the present invention have potential applications in the medical field, both in drug development and in gene therapy.
  • random mutagenesis has been instrumental in generating modified enzymes for the management of cancer [Encell L. P. et al., Nat. Biotechnol. 17: 143-7 (1999)].
  • mutants designed to reduce the side-effects of cancer therapy and mutants with improved pro-drug-activating properties.
  • Examples of the former include: thymidylate synthase resistant to 5-flourouracil; 6-methyguanine-methyl transferase resistant to alkylating agents and to 6-benzoguanine; and dihydrofolate reductase resistant to metrotrexate.
  • Examples of the latter include thymidylate kinase with enhanced specificity for gancyclovir or acyclovir, deoxycytidine-kinase mutants specific for Ara-C, and a cytosine deaminase specific for 5-fluorocytosine.
  • the error-prone Pol I mutants of the invention also have potential applications in promoting enzyme modification by random mutagenesis in areas as diverse as chemical synthesis, bioremediation, and food processing [reviewed in Chirumamilla et al., Mol. Cell Biochem. 224: 159-68 (2001); Schmidt-Dannert et al., Trends Biotechnol. 17: 135-6 (1999)].
  • the Pol 1 mutants of the invention may be used to generate enzymes with altered substrate specificity, including altered esterases, Upases, cytochrome oxidases, and dioxygenases, and enzymes with improved catalysis in non-natural environments, such as alkaline conditions, heat, cold, and/or presence of metal chelators.
  • Pol I mutants may be used to generate enzymes with altered substrate specificity to improve the efficiency and enantiomeric purity of chemical synthesis. Enzymes resistant to heat and to the presence of metal chelators may be obtained by the error-prone Pol I mutagenesis to improve rates of biocatalysis in chemical synthesis. Pol I mutants may be also used to generate enzymes that confer resistance to alkaline conditions for degradation of dyes in laundry, or resistance to cold conditions in food processing applications.
  • the present invention has foreseeable applications in emerging fields, including biotechnology, gene therapy, and bioremediation.
  • DNA-specific reagents such as recombinases and restriction enzymes [Buchholz et al., Nature Biotechnol. 19: 1047-52 (2001); Santoro et al., Proc. Natl. Acad. Sci. U S A, 99: 4185-90 (2002)]
  • enzymes for alkane degradation Belhaj et al., Res. Microbiol. 153: 339-344 (2002)
  • a method for generating enhanced mutagenesis that can be targeted to a sequence of interest in which error-prone Pol I mutants bearing amino- acid substitutions in the motif A and/or B, for example, including amino-acid substitutions at positions I709N/F and A759R, are expressed in host strains under carefully controlled culture conditions, as described below in Example 2.
  • the method comprises transforming a prokaryotic host strain with an expression vector having any of numerous forms that encodes one or more error- prone Pol I mutants, and transforming a second vector, such as a plasmid that encodes one or more target genes.
  • the method comprises incorporating one or more copies of genes or fragments that encode error-prone Pol I within the chromosomes of cell lines or host strains, and subsequently transforming the population of cells expressing the mutants with a vector, such as a plasmid, that encodes one or more target genes.
  • controlled conditions comprise growing a culture of transformed cells in a rich media and letting the culture reach and maintain a stationary growth phase, such as a growth stage obtained 15 hours after inoculation.
  • culture conditions by which error-prone Pol I achieves optimal mutagenic performance include: (1) growing the transformed host strain cultures at a cell density indicative of exponential growth (e.g., OD600-0.5); (2) diluting the culture to a low concentration (e.g., 1 :10 5 ) in nutrient-rich medium (e.g., 2XYT) pre-warmed at 37 °C; (3) incubating the culture for an additional time (e.g., 15 min. at 37 °C); and (4) placing the culture in a 37 °C shaker to reach a point of saturation (e.g., 15 hours).
  • a cell density indicative of exponential growth e.g., OD600-0.5
  • a low concentration e.g., 1 :10 5
  • nutrient-rich medium e.g., 2XYT
  • the error-prone Pol I mutants may be used to produce labeled plasmid DNA or fragments thereo, in vivo.
  • one or more labeled nucleotide or nucleoside analogs may be added to the culture medium to be inco ⁇ orated into the replicated copies of target plasmid DNA.
  • the error-prone Pol I mutants may be purified from cell extracts as recombinant proteins, and added to in vitro reactions containing a target sequence for microarray analysis or other high-throughput DNA labelling procedures or for sequencing pu ⁇ oses.
  • dNTPs Modified deoxynucleoside triphosphates
  • nucleotide analogs including dATPs, dGTPs, dCTPs, dTTPs, dUTPs, and dITPs, and related analogs
  • dATPs deoxynucleoside triphosphates
  • dGTPs dGTPs
  • dCTPs dTTPs
  • dUTPs dUTPs
  • dITPs Modified deoxynucleoside triphosphates
  • These nucleotides and nucleosides may be modified by covalent attachment of groups for detection by fluorescence (rhodamine green, fluorescein), chemiluminescence (biotin), or radioactivity ( ⁇ [ 32 P]).
  • the nucleoside and nucleotide analogs may be synthesized by known methods in the art.
  • error-prone Pol I mutants bearing mutations in motif A and/or motif B can increase the frequency of mutagenesis, between 4 and 5 orders of magnitude above that of wild type Pol I, with up to a 400-fold differential relative to the chromosome, as shown in Example 3 provided below.
  • the compositions and methods permit mutagenesis targeting nucleotides located distantly from the ori including a distance of 3700 bp, far exceeding the 400 bp limit reported by previous investigators.
  • a broad variety of prokaryotic and eukaryotic genes can be targeted by the present invention.
  • compositions and methods of the invention permit the targeting of the sequence of interest, resulting in a diverse mutation spectrum and a wide distribution of mutations, as shown in Example 4 provided below.
  • the mutagenesis system of the present invention provides the additional advantage, with respect to existing mutator strains, so that the mutagenesis system representing one embodiment of the current invention may be readily adapted to different strains, as shown in Example 6 provided below.
  • Suitable host strains include: (1) strains endogenously expressing a temperature-sensitive DNA Pol I allele, (2) a wild type DNA polymerase; and (3) both wild type DNA pol and wild type DNA repair phenotypes.
  • inducible promoters may be used.
  • inventions of the in vivo mutagenesis system are directed to a large number of existing strains known to be deficient in specific enzymes and amenable to complementation such as the ⁇ 2913recA strain defective in thymidine synthase described above.
  • compositions and methods permit the accumulation of beneficial mutations within the target gene, in a continuous culture.
  • Two independent selections with increasing concentrations of aztreonam were carried out under optimized mutagenic conditions to obtain 23 sequences representing ⁇ - lactamase variants from each selection, as shown in Example 4 and 7, provided below.
  • Two known amino acid substitutions were identified in these selections: E104K (glutamic acid changed to lysine at position 104) and R164H (arginine changed to histidine at position 164) in selection 1 and to S (arginine changed to serine at position 164) in selection 2.
  • a novel mutation, the G267R (glycine changed to arginine at position 267) was identified in selection 1.
  • the mutations can occur sequentially in this system as exemplified by the introduction of the G267R mutation following the E104K and R164H mutations, which can be found in a single clone that encoded a silent mutation also present in all the other plasmids carrying the E104K and R164H mutations that were sequenced. No other silent mutations were found.
  • Table 4 in Example 7 presents the aztreonam phenotypes corresponding to different combinations of these amino acid substitutions after subcloning into vectors that have not been replicated by error-prone Pol I mutants to ensure that no other mutations were present.
  • Relatively mild mutagenesis conditions are more than offset by the large size of the pool (approximately 10 11 plasmids) and by the discriminating power of iterative functional selection.
  • Finding three relevant mutations in a single ⁇ -lactamse sequence, with probability of 10 "10 [Long-McGie et al., Biotechnol. Bioeng. 68: 121 -5 (2000)] is an illustration of the efficient exploration of sequence space allowed by the embodiments of the present invention.
  • compositions and methods can be used for prognostic pu ⁇ oses in predicting the evolution of novel resistance mutations, such as the G267R, based on the fact that the selection step can identify the most common mutations found in clinical isolates.
  • the embodiments of the invention are unlike most other mutagenesis approaches that yield a more biased representation relative to naturally occuring mutants [See Orencia et al., Nat. Struct. Biol. 8: 238-242 (2001)]. Mutations at positions El 04 and R164 are the most frequently found in naturally-occurring clinical isolates (http://www.lahey.org/studies/temtable.htm).
  • Example 1 methods for constructing low-fidelity E. coli Pol I mutants engineered in motif A and or B are provided.
  • culture conditions optimized for elevated frequency of plasmid-specific in vivo mutagenesis are provided.
  • Example 3 the synergistic effect on the efficacy of plasmid targeting in vivo mediated by the D424A I709N A759R Pol I mutant and its sensitivity to culture conditions is provided.
  • Example 4 the spectrum and frequency of mutations introduced into target sequence/ ⁇ -lactamase upon D424A I709N A759R Pol I mutant expression are provided.
  • Example 5 the frequency of mutations in a target plasmid as a function of the distance from the origin of replication (ori) is provided.
  • Example 6 the effect of D424A 1709N A759R Pol expression on the frequency of in vivo mutagenesis in host cells that endogenously produce wild type Pol I and are proficient in DNA repair is provided.
  • Example 7 an example of directed evolution under selective pressure such as increasing concentration of aztreonam is provided.
  • E. coli OW5apolA was amplified by colony polymerase chain reaction with 59- ATATATATAAGCTTATGGTTCAGATCCCCCAAAATCCACTTATC-39 and 59- ATATATATGAATTCTTAGTGCGCCTGATCCCAGTTTTCGCCACT-39 as primers.
  • pECpol I To create pECpol I, the 3-kilobase pair amplified fragment was digested with Hindlll and EcoRI, and then cloned under the lactose promoter into pHSG576, a low copy-number plasmid that has a pol I-independent origin and chloramphenicol as a selectable marker. Site-directed mutagenesis was performed on pECpol I to introduce silent mutations C to A at position 2,067 and G to C at position 2,214 of the polA gene to create Accl and Eagl sites, respectively, that flank the sequence encoding motif A. The resulting plasmid was named pECpol IS.
  • Plasmids encoding the I709N and I709F motif A mutants of DNA polymerase were isolated from a Pol I library by genetic selection.
  • a random library was constructed by annealing two single-stranded DNA oligonucleotides containing segments with random sequences:
  • Oligo 1 was a 104-mer corresponding to the sense nucleotides 2,053-2,156, and containing an Accl site for cloning (5'- GAAGGTCGTCGTATACGCCAGGCGTTTATTGCGCCAGAGGATTAT [GTGATTGTCTCAGCGGACTACTCGCAGATTGAACTGCGC]ATTATGGCGC ATCTTTCGCG-3');
  • Oligo 2 was a 89-mer corresponding to anti-sense strand nucleotides 2,225-2,137 and containing an Eagl site (5'-AACACTTC TGCGGCCGTTGCCCGGTGGATATCTTTTCCTTCCGCGAATGCGGTCAGCAA GCCTTTGTCACGCGAAA
  • the bracketed nucleotides in Oligo 1 were synthesized to contain 88% wild-type nucleotide and 4% each of the other three nucleotides at every position.
  • the 20-base pair complementary regions of hybridization are underlined.
  • Oligo 1 and Oligo 2 were annealed at their nonrandom complementary regions by mixing 250 pmol of each in 20 ⁇ l of H 2 0 and heating to 95 °C for 5 min, followed by cooling for 2 h to room temperature.
  • the partially duplex oligonucleotide was extended by incubation with 50 units of E.
  • the remainder of the library was amplified by growing the transformed E. coli XLl-Blue in 3 liters of 2XYT medium for 16 h at 37 °C, and the random library, pECpolLib, was then purified.
  • the pECpolLib was transformed into JS200 cells (with plasmids pHSG576, pECpolIS, pECpoldum as controls) and selected for survival on nutrient agar plates at 37 °C overnight. Only paired samples containing less than 1,500 colonies at 30 °C were analyzed because dense plating of the cells leads to elevated background at 37 °C. Approximately, 280 colonies that grew at 37 °C were randomly picked and sequenced and found to contain between 1 and 2 amino acid substitutions.
  • the A759R and S756E amino acid substitutions in motif B were introduced by site-directed mutagenesis into plasmids I709N, I709F, D424A I709N and D424A I709F to generate the mutants I709N A759R, D424A I709F A759R, D424A D1709N A759R, and D424A I709F A759R.
  • QuickchangeTM (Stratagene® La Jolla, CA) was used with the following mutagenic primers: Pol I S756E-F 5'-CCAGCGAGCAA CGCCGTGAGGCGAAAGCGATCAACTTTGG-3'; Pol I S756E-R 5'-CCAAAGT TGATCGCTTTCGCCTCACGGCGTTGCTCGCTGG-3'; Pol 1 A759R-F 5'- CGCCGTAGCGCGAAACGGATCAACTTTGGTCTGATTTATGGC-3'; Pol I A759R-R 5'- GCCATAAATCAGACCAAAGTTGATCCGTTT
  • FIG. 5A provides an example of "initial" culture conditions and a method for inducing in vivo mutagenesis by expression of error-prone Pol I that is representative of one conventional method used by those skilled in the art prior to the development of "optimal" culture conditions and methods embodied in the invention.
  • error-prone Pol I There are two previous reports of a 3-10 fold increase in plasmid mutagenesis relative to chromosomal mutagenesis using culture conditions similar to initial conditions.
  • the polymerase used was Pol I containing an inactivated proofreading domain [Fabret et al., Nucleic Acids Res. 28: E95 (2000)].
  • the other example developed by the present inventors used the D424A I709F as an error-prone Pol I [Shinkai, A., and Loeb, L.A. J. Biol. Chem. 276: 46759-64 (2001)].
  • the improvement in the frequency and in the targeting of mutagenesis were attributed to the following four variables: (1) dilution of the initial inoculum (to at least 1:10 5 ), (2) growth of cells in 2XYT, (3) pre-warming cells to 37 °C, and (4) continued growth of the cultures past the point of saturation (typically 15-17h).
  • Example 2 illustrates the individual culture parameters found to have an effect on mutagenesis by error-prone Pol I expression.
  • a system for random in vivo mutagenesis should exhibit frequent mutations throughout a targeted gene, from the 5'end to the 3'end, and as few mutations that are non-target specific. Culture conditions were varied to achieve optimal mutagenic performance according to these criteria. Cultures should be allowed to reach saturation.
  • Other variables that contributed to the efficacy of random mutagenesis included the type of culture medium, the temperature of the medium at the time of inoculation, and the initial inoculum concentration. Careful optimizations of culture conditions achieved by trial and error are critical for obtaining mutagenesis resulting in a high target specificity and broad distribution of mutations.
  • the JS200 strain was initially described as SCI 8-12 [Witkin, E. M. and Roegner-Maniscalco, V., J. Bacteriol. 174: 4166-8 (1992)], and has the following genotype: SC-18 recA718 polA12 uvrA155 trpE65 lon-11 sulAl. SC-18 carries tetracycline resistance and is insensitive to ⁇ phage. PolA12 is a temperature sensitive allele of Pol I [Monk, M. and Kinross, J., J. Bacteriol. 109: 971-8 (1972)].
  • Rec718 allele originated from an unstable recombinant obtained in a conjugation between a recA441 K12 donor and a rec A * B/r-derived recipient [Witkin, E. M., Mol. Gen. Genet. 185: 43-50 (1982)]. It carries two base substitutions, one that allows the RecA protein to become constitutively activated, and one partial suppressor [(McCall et al., J. Bacteriol. 169: 728-34 [1987)].
  • reporter plasmids Preparation of reporter plasmids can be described as follows.
  • the reporter plasmids to measure the reversion frequency of the ⁇ -lactamase gene were modifications of plasmid pGPS3 (New England Biolabs Inc., Beverly, MA).
  • This plasmid contains a pUC19 (ColEl -type) origin of replication and the npt and amp genes for kanamycin and carbenicillin selection.
  • a G-to-T transversion at position 76 of the ⁇ -lactamase gene was introduced by site- directed mutagenesis, changing the codon GAA for Glu26 to the ochre stop codon TAA.
  • the reporter plasmids used to measure ⁇ -lactamase reversion frequency were pLA230, and pLA2800, carried 230 bp and 2800 bp downstream from the pUC19 origin of replication [Shinkai, A. & Loeb, L.A., J.Biol. Chem. 276, 46759-46764 (2001)].
  • Plasmid pGPSori corresponds to pLA230 but with the wild-type ⁇ -lactamase gene instead of the interrupted version.
  • pGPS3 was used as the template for primers 5'- GC ACCCGACATAC ATGTCCTATTTGTTTATT-3 ' and 5 ⁇ AACTTGGTCGGTACCTTACCAATGCTTAATC-3.
  • the pLA2800 corresponds to pGPS3 encoding an ochre stop codon at position 76 of the ⁇ -lactamase gene (2748 bp from the origin of replication).
  • Preparation of competent cells can be described as follows. Single colonies growing on LB plates with appropriate antibiotic selection were picked and incubated overnight without shaking at 30 °C in 50 ml of LB plus antibiotic.
  • the bacterial culture was shaken for 1 h at 30 °C, it is transferred to a flask containing 450 ml LB antibiotic, and left in the 30 °C shaker for 3-4 hours (to an OD 6 oo of 0.5-1).
  • Cells were chilled on ice for 20 minutes, pelleted in a Sorval® RC 5B Plus centrifuge and washed twice in 10% glycerol. The pellet was resuspended in ⁇ 2ml 10% glycerol, aliquoted in 120 ⁇ l aliquots, and quick-frozen on dry ice.
  • competent cells were made using the Poll plasmid first, and subsequently transformed with the reporter plasmids.
  • Transformations were performed using a A Biorad Gene Pulser TM apparatus (set to 400 ⁇ , 2.20 V and 2.5 ⁇ FD). After the electric shock, cells were resuspended in 1 ml LB media, left to shake for lh at 30 °C, and plated in LB plates with the appropriate antibiotics for plasmid selection. Single colonies were picked into 5ml LB with the appropriate antibiotics and grown overnight at 30 °C with no shaking. In the case of XL1 Blue cells, since temperature or media is not an issue, a more standard protocol involving the resuspension in 2XYT medium, shaking at 37 °C for 30 minutes, and growth of single colonies in LB media in a 37 °C shaker for 16h is followed.
  • Transformation with a reporter gene results most frequently in the loss of the temperature-sensitive phenotype.
  • Replication of reporter plasmids likely depletes the limited Pol I functional reserves of JS200 cells even under permissive conditions, favoring the outgrowth of revertants and/or suppressors.
  • the plasmid carrying Pol I was used for the first transformation to make competent cells, which were used subsequently to transform the reporter plasmids.
  • the ⁇ -Lactamase reversion assay was performed in the following way. E. coli JS200 transformant strains carrying Pol I (wild type or different low-fidelity mutants) in the pHSG576 plasmid (chloramphenicol-resistant (cm 1 )) were retransformed with a reporter plasmid (kanamycin (kan 1 )). Single colonies exhibiting double resistance (cm r , kan r ) were picked into 5 ml LB (plus tet, kan, cm) and grown overnight without shaking. After lhour shaking at 30 °C, the cultures (OD ⁇ 0.5) were diluted 1:10 s in 5 ml 2XYT media pre-warmed at 37 °C.
  • Table 1 summarizes the results of assays characterizing the frequency and the degree of mutagenesis targeting (results shown in FIG. 6).
  • JS200 cells were transformed with either wild type Pol I or respective Pol I mutators, and reporter plasmid pLA230.
  • the frequency of ⁇ -lactamase reversion (normalized to wild type) is indicative of the frequency of mutagenesis in a given target gene.
  • the ratio of rifampicin resistance relative to carbenicillin resistance reflects the frequency of chromosomal mutagenesis.
  • Optimized conditions represent cultures grown under permissive conditions to OD600-0.5 that were diluted 1 :10 5 in 2XYT pre-warmed at 37 °C, incubated an additional 15 min. at 37 °C, and placed in the 37 °C shaker for 15 hours (saturation). Mutagenesis frequencies were determined by ⁇ -lactamase reversion assay (target within plasmid) or by scoring rifampin-resistant colonies (target within chromosome), and the reported values have been normalized against the wild type.
  • the relative frequency of plasmid versus chromosomal mutagenesis for each mutant polymerase was obtained after normalizing to that found for the wild type polymerase. This inco ⁇ orates variable such as the different nature of the assays (forward assay (Rif) versus ⁇ - lactamase reversion assay), and the difference in target numbers (single copy (Rif) versus a multicopy ⁇ -lactamase).
  • Example 3 characterizes mutagenesis associated with expression of different error-prone Pol I mutants and its sensitivity to culture conditions (FIG. 5A and 5B).
  • Pol I mutants were tested: D424A I709N, A759R, D424A A759R, I709N A759R and D424A I709N A759R (a subset of which is presented in FIG. 6).
  • Table 1 summarizes these results.
  • the effect of D424A I709N expression under initial conditions is comparable to published data [Shinkai, A., and Loeb, L.A. J. Biol. Chem.
  • D424D A759R mutation results in a frequency of mutagenesis that compares to that of D424A I709N. Similar to motif A mutations, elevated mutagenesis is dependent on the simultaneous inactivation of the proofreading domain. These results confirm that position A759 in motif B is a critical determinant of fidelity in E. coli. Strikingly, expression of the I709N A759R D424A triple mutant results in mutation frequencies that are more than additive, 6 to 26 times above those of each double mutant (same applies to I709F A759R D424A).
  • Table 2 shows the mutation spectrum of mutations located outside the ochre stop codon in the ⁇ -lactamase gene identified in cells expressing D424A I709N A759R Pol I.
  • the numbers within the heading represent the location of the sequence relative to the origin of replication. Given the nature of the assay, which required functional expression, frameshifts and deletions were not determined.
  • Example 4 provides an illustration of the mutagenic spectrum resulting from error-prone Pol I expression.
  • 158 carbenicillin-resistant clones were sequenced. All 155 of these clones showed mutations in the ochre codon. Of these, only 2 changed to another stop codon (both to opal), which gives an overall specificity of 96.8% for the reversion assay. Wild type sequence was present in 148 of the remaining 153 sequences, in varying amounts, from trace amounts to about 90%, which is consistent with mutations encoded in a multicopy plasmid with diverse degrees of dominance.
  • the number of target plasmids present in cells expressing I709N A759R D424A Pol I was determined in order to estimate the mutation load and found to be of only 10 copies/cell (FIG. 7). This is in contrast with -100 copies/cell in cultures expressing the wild type Pol I. This effect of the Pol I point mutations on target plasmid copy number decreases the size of the mutant libraries by 10-fold. However, this reduction in the number of targets per cell may have improved the selection efficiency, as each new mutation is expected to represent a larger fraction of expressed protein, and is therefore more likely to have a larger impact on the phenotype.
  • the frequency of stop codon reversion was in the order of one in 500 cells (FIG. 6). Given that 10 target plasmids/cell were estimated, this translates into one reversion in 5000 codons. Since 2 of the 9 possible base pair substitutions at the ochre codon are not permissible, that is the equivalent of 1 mutation in 3,900 codons. Assuming an even distribution of mutations, i.e., that mutations at the ochre stop codon are representative of those of every other codon in the protein, results an estimated mutation frequency of 1 mutation in 11,500 bp (3 x 3900). The highest mutation frequency reported in vivo is 0.5 mutations/Kbp [Greener, A.
  • JS200 cells expressing the D424A I709N A759R polymerase and with the reporter plasmid pLA230 were grown under optimal conditions for mutagenesis and plated on plates containing 50 ⁇ g/ml carbenicillin. Single carbenicillin-resistant colonies were grown. Their plasmids were extracted and the sequence at the ochre codon was determined using oligonucleotide Blac-5. Secondary mutations were confirmed using the following oligonucleotides: Blac-5 5'-TTACGGTTCCTGGCCTTTTGC-3'; B lac-6 5 ' -GGTTG AGTACTC ACCAGTCAC-3 ' ; Blac-7 5'-TCCGATCGTTGTCAGAAGTAA-3'; and
  • FIG. 8B demonstrates the frequency of mutagenesis as a function of distance from the origin of replication (ori), determined to assess the level of mutagenic coverage by error-prone Pol I mutants containing single and double mutations in the active site.
  • the JS200 cells were transformed with either wild type or with different error-prone Pol I mutants and one of the following reporters with increasing distance between the ori and the position of the ochre stop codon: pLA230, pLA700, pLA1400, pLA2800, and pLA3700.
  • Pol I has been reported to synthesize -400 bp in the leading strand downstream of ColEl origin [Sakakibara, Y. & Tomizawa, J., Proc. Natl. Acad. Sci. U S A 71: 1403-1407 (1974)], at which point, replication of both leading and lagging strands is taken over by the Pol III replisome [Staudenbauer, W.L., Mol. Gen. Genet. 149: 151-158 (1976)]. Thus, most Pol I-dependent mutations were expected to cluster in the 5' end of the target gene.
  • Example 5 demonstrates that target sequences at a distance of at least 3700 bp from the ori are amenable to mutagenesis by error-prone Pol I expression.
  • Example 2 The preparation of pLA230 and pLA2800 are provided in Example 2, and the other reporters were derived from plasmids pLA2800 and pGPS ⁇ as follows:
  • the pLA3800 was generated by amplification of the entire npt (kan 1 ) gene using the synthetic oligonucleotides 5'-
  • the 980 bp amplified fragment was cloned into the Kpnl site of plasmid pLA2800, adding one extra copy of npt and moving the stop codon to 3691 bp of the plasmid origin of replication.
  • the pLA2200 resulted from excising of a Sal I 1517 bp fragment from plasmid pLA3800 and religating the plasmid backbone. This brought the stop codon to 2174 bp of the plasmid origin of replication.
  • the pLA1400 was generated by cloning a PCR-amplified npt gene into the Sad and Aflll sites of pLA2800, bringing the ⁇ -lactamase ochre codon to 1403 bp from the ori.
  • the oligonucleotides containing Sad and Afllll adapters used for amplification were 5 '-CATCGAGCTCTTAACCAATTCTGATTAGAAAAAC-3 ' and 5'-GATGACATGTCTAGATTTAAATGATATCGGATCC-3 ' .
  • the pLA700 resulted from subcloning the PCR-amplified ⁇ -lactamase reporter into Swal and Spel sites of pGPS ⁇ .
  • oligonucleotides used were 5'-CATCGATATCTTACCAATGCTTAATCAGTG-3' and 5'-GATGACTAGTCCCTATTTGTTTATTTTTCT-3', containing EcoRV and Spel adapters respectively. This places the ochre stop codon in the ⁇ -lactamase gene only 709 nucleotides away from the origin of replication.
  • FIG. 9 (graphical illustration of data in Table 3) demonstrates the plasmid- specific mutation frequency mediated by error-prone Pol I mutants in a Pol I proficient strain, to determine if expression of chromosomal wild type Pol I interferes with error-prone Pol I mutagenesis.
  • XLl-Blue cells a strain that expresses wild type Pol I, were transformed with Pol I mutator (D424 I709N A759R) and reporter plasmid pLA230.
  • RESULTS The critical genetic material is provided in a vector and expression of wild-type Pol I and/or intact DNA repair in the host do not significantly interfere with mutagenesis. Thus, random mutagenesis may be performed in strains specifically designed for complementation by a targeted gene.
  • FIG. 9 and Table 3 illustrates this point demonstrating that error-prone Pol I mutants are co- dominant in a host expressing wild-type Pol I and proficient in DNA repair (XL-1 Blue).
  • Pol I overexpression of error-prone Pol I increases target plasmid mutagenesis in these cells, by competing with the wild type Pol I for replication of the target plasmid. If overexpressed, error-prone Pol I can be expected to outcompete the wild type.
  • Fig. 9 shows that overexpression of of D424A I709N A759R Pol I in XL-1 Blue cells (by inducing expression from the tac promoter with IPTG) further increases plasmid mutagenesis to frequencies comparable to those obtained in JS200.
  • the higher background relative to JS200 that was observed may be due to the GlnV mutation (an amber suppressor with some activity against ochre) and therefore should not affect this conclusion.
  • Rifampicin resistance was comparable between the two strains, indicating Pol I mutagenesis is still plasmid- restricted in XLl-Blue cells.
  • XLl-Blue cells are FXTnlO proA + B + laclq ⁇ (lacZ) M15/recAl endAl gyrA96(Nalr) thi hsdR17 (r ⁇ m ) glnV44 relAl lac and are commercially available (can be purchased from Statagene ® for example).
  • Cells were grown under appropriate antibiotic selection: tetracycline (Sigma® St.Louis MO) at 12.5 ⁇ g/ml, chloramphenicol (Sigma® St.Louis MO) at 30 ⁇ g/ml, and/or kanamycin (Island Scientific, Bainbridge Island, WA) at a concentration of 50 ⁇ g/ml.
  • Table 4 presents the phenotypes of the TEM-1 mutations that were identified as a result of the selections performed to establish the applicability of the system to directed evolution of enzymes.
  • JS200 cells that were co-transformed with a plasmid encoding D424A I709N A759R Pol I and a second plasmid encoding the target TEM- 1 ⁇ -lactamase, were subjected to selective pressure under increasing concentrations of aztreonam.
  • Controls included the following transformations: (a) wild type Pol I with wild type ⁇ -lactamase; (b) D424A I709N A759R Pol I with a plasmid devoid of ⁇ - lactamase; and (c) wild type Pol I with a plasmid devoid of ⁇ -lactamase.
  • Viable cells were expanded by growing a 1 :10 dilution at the same concentration of drug, after which another 1:10 dilution was selected in 32 ⁇ g/ml aztreonam. At this concentration, none of the controls showed significant growth. Surviving cells were plated at 64 ⁇ g/ml aztreonam. Plasmids were obtained from single colonies and the TEM-1 ⁇ -lactamase was directly sequenced using specific primers.
  • Aztreonam was purchased from the Drug Services of the University of Columbia
  • the aztreonam dose-response curve for JS200 was obtained under the conditions used for Pol I mutagenesis (1:10 5 inoculum, pre-warmed 2XYT, 37 °C shaker for 15h).
  • the inhibitory concentration of Aztreonam that kills >99% of the cells (IC 9 ) was 0.2 ⁇ g/ml. This was true for both JS200 cells transformed with pGPS3ori and cells transformed with pGPS3 ⁇ , confirming that wild-type ⁇ -lactamase does not confer significant aztreonam resistance.
  • JS200 cells were transformed with a plasmid enconding D424A I709N A759R Pol I and pGPSori, a plasmid encoding wild type ⁇ -lactamase starting 150bp downstream from the ori.
  • Controls included cells expressing the following: (a) Wild type Pol I and wild type ⁇ -lactamase; (b) D424A I709N A759R Pol I and a target plasmid carrying a large ⁇ -lactamase deletion; and (c) wild type Pol I and the deleted ⁇ -lactamase. Two independent selections were carried out under "optimized" mutagenic conditions.
  • Viable cells were expanded by growing a 1 : 10 dilution at the same concentration of drug, after which another 1 :10 dilution was selected in 32 ⁇ g/ml aztreonam. None of the controls survived at this point, indicating that the presence of both error-prone Pol I and ⁇ -lactamase was essential for resistance under these conditions.
  • Surviving cells were plated at 64 ⁇ g/ml aztreonam.
  • Plasmids were obtained from single colonies and the TEM ⁇ -lactamase was directly sequenced using specific primers. Individual colonies were picked from aztreonam plates and grown under permissive conditions (30°C, no shaking) to avoid further mutagenesis in the presence of 10 ⁇ g/ml aztreonam. Plasmids were extracted from 3 ml of each of these clones using the Perfectprep® miniprep kit from Eppendorf AG and resuspended in 50 ⁇ l water. They were sequenced by using the primers Blac-5,-6,-7,-8 (Example 4).
  • the sites Haelll, Seal and Fspl (unique within the target plasmid) were used to subclone the mutations identified in the ⁇ -lactamase ORF by aztreonam selection into the vector encoding ⁇ -lactamase and to generate all possible mutant combinations. These constructs were transformed into JS200 cells carrying the wild- type Pol I plasmid to maintain the same genetic background without inducing further mutagenesis, and grown in the absence of any ⁇ -lactam. Cells were diluted to the standard inoculum of 10 5 cfu/ml and grown for 16h in the presence of increasing concentrations of aztreonam.
  • the IC50S were established by plotting OD 6 oo against drug concentration and finding the concentration that reduces survival by 50%. To account for variations in expression in individual clones, two independent experiments were performed and averaged. The standard deviation between the two experiments was in the order of 30%.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne des formes de mutant de polymérase I présentant des mutations dans le motif A et/ou dans le motif B dans le domaine actif qui augmentent les taux d'erreur pendant la réplication. Cette invention concerne aussi des construits plasmidiques d'expression et des lignées cellulaires permettant d'exprimer ces mutants de polymérase d'ADN peu fidèles. Cette invention concerne aussi des mutants de polymérase I d'ADN peu fidèles destinés à générer des bibliothèques de gènes mutagénisés aléatoirement, lesquels peuvent être procaryotes ou eucaryotes. La mutagenèse aléatoire implique le couplage de la mutagenèse et de la sélection en culture continue pour une itération pratique, laquelle permet d'obtenir diverses plages de substitutions de paires de base généreusement réparties le long de la séquence. Parmi certains avantages, on minimise les dégradations nocives de l'ADN chromosomique et on permet une adaptation à des souches qui peuvent faire l'objet de complémentation, ce qui facilite considérablement la génération et l'identification d'enzymes aux propriétés modifiées.
PCT/US2003/016798 2002-05-31 2003-05-29 Mutants de polymerase i d'adn sujet a l'erreur et techniques de mutagenese aleatoire ciblee en culture continue utilisant ces mutants de polymerase i d'adn sujet a l'erreur WO2003102213A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP03736735A EP1504091A4 (fr) 2002-05-31 2003-05-29 Mutants de polymerase i d'adn sujet a l'erreur et techniques de mutagenese aleatoire ciblee en culture continue utilisant ces mutants de polymerase i d'adn sujet a l'erreur
AU2003237269A AU2003237269A1 (en) 2002-05-31 2003-05-29 Error-prone DNA polymerase I mutants and methods for targeted random mutagenesis in continuous culture using error-prone DNA polymerase I mutant
JP2004510449A JP2005528114A (ja) 2002-05-31 2003-05-29 変異性ｄｎａポリメラーゼｉ突然変異体、および連続培養において変異性ｄｎａポリメラーゼｉ突然変異体を用いた、標的とされたランダム突然変異誘発のための方法
CA002485203A CA2485203A1 (fr) 2002-05-31 2003-05-29 Mutants de polymerase i d'adn sujet a l'erreur et techniques de mutagenese aleatoire ciblee en culture continue utilisant ces mutants de polymerase i d'adn sujet a l'erreur

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38494402P 2002-05-31 2002-05-31
US60/384,944 2002-05-31

Publications (2)

Publication Number Publication Date
WO2003102213A2 true WO2003102213A2 (fr) 2003-12-11
WO2003102213A3 WO2003102213A3 (fr) 2004-06-17

Family

ID=29712109

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/016798 WO2003102213A2 (fr) 2002-05-31 2003-05-29 Mutants de polymerase i d'adn sujet a l'erreur et techniques de mutagenese aleatoire ciblee en culture continue utilisant ces mutants de polymerase i d'adn sujet a l'erreur

Country Status (5)

Country Link
EP (1) EP1504091A4 (fr)
JP (1) JP2005528114A (fr)
AU (1) AU2003237269A1 (fr)
CA (1) CA2485203A1 (fr)
WO (1) WO2003102213A2 (fr)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007039461A1 (fr) * 2005-09-21 2007-04-12 Andreas Meyer Génération in vivo de banques d'adn, d'arn, de peptides et de protéines
JP2007520227A (ja) * 2004-02-05 2007-07-26 ライニッシェ フリードリッヒ ヴィルヘルムス ウニヴェルジテート ボン 誤対合識別の増加を有する変異ｄｎａポリメラーゼ
WO2012139748A1 (fr) * 2011-04-11 2012-10-18 Roche Diagnostics Gmbh Adn polymérases avec une activité améliorée
US8603797B2 (en) 2010-03-17 2013-12-10 Cornell University Methods and compositions for targeted mutagenesis in bacteria
US9080156B2 (en) 2011-12-08 2015-07-14 Rocher Molecular Systems, Inc. DNA polymerases with improved activity
US9428782B2 (en) 2011-12-08 2016-08-30 Roche Molecular Systems, Inc. DNA polymerases with improved activity
US9441269B2 (en) 2011-12-08 2016-09-13 Roche Molecular Systems, Inc. DNA polymerases with improved activity
WO2017019617A1 (fr) * 2015-07-24 2017-02-02 Manel Camps Système pour la mutagenèse continue in vivo pour faciliter une évolution dirigée
CN108130318A (zh) * 2018-02-28 2018-06-08 深圳市草履虫生物科技有限公司 突变型Taq DNA聚合酶、免核酸提取直接PCR扩增的试剂盒及其应用
CN108588050A (zh) * 2018-05-14 2018-09-28 北京艾克伦医疗科技有限公司 Dna聚合酶以及核酸检测方法和试剂盒

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE143057T1 (de) * 1994-10-17 1996-10-15 Harvard College Dns polymerase mit veränderter nukleotid- bindungstelle
US6306588B1 (en) * 1997-02-07 2001-10-23 Invitrogen Corporation Polymerases for analyzing or typing polymorphic nucleic acid fragments and uses thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
PATEL ET AL.: 'A single highly mutable catalytic site amino acid is critical for DNA polymerase fidelity' J. BIOL. CHEM. vol. 276, no. 7, 16 February 2001, pages 5044 - 5051, XP001002848 *
PATEL ET AL.: 'Insights into DNA polymerization mechanisms for structure and function analysis of HIV-1 reverse transcriptase' BIOCHEMISTRY vol. 34, April 1995, pages 5351 - 5363, XP002973167 *
See also references of EP1504091A2 *
SUZUKI ET AL.: 'Low fidelity mutants in the O-helix of thermus aquaticus DNA polymerase I' J. BIOL. CHEM. vol. 272, no. 17, 25 April 1997, pages 11228 - 11235, XP002062866 *

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007520227A (ja) * 2004-02-05 2007-07-26 ライニッシェ フリードリッヒ ヴィルヘルムス ウニヴェルジテート ボン 誤対合識別の増加を有する変異ｄｎａポリメラーゼ
WO2007039461A1 (fr) * 2005-09-21 2007-04-12 Andreas Meyer Génération in vivo de banques d'adn, d'arn, de peptides et de protéines
US8603797B2 (en) 2010-03-17 2013-12-10 Cornell University Methods and compositions for targeted mutagenesis in bacteria
US9637726B2 (en) 2011-04-11 2017-05-02 Roche Molecular Systems, Inc. Methods for conducting primer extension using DNA polymerases with improved activity
WO2012139748A1 (fr) * 2011-04-11 2012-10-18 Roche Diagnostics Gmbh Adn polymérases avec une activité améliorée
US9017979B2 (en) 2011-04-11 2015-04-28 Roche Molecular Systems, Inc. DNA polymerases with improved activity
US10597644B2 (en) 2011-04-11 2020-03-24 Roche Molecular Systems, Inc. DNA polymerases with improved activity
CN103492559A (zh) * 2011-04-11 2014-01-01 霍夫曼-拉罗奇有限公司 具有改进活性的dna聚合酶
US9890366B2 (en) 2011-12-08 2018-02-13 Roche Molecular Systems, Inc. DNA polymerases with improved activity
US9441269B2 (en) 2011-12-08 2016-09-13 Roche Molecular Systems, Inc. DNA polymerases with improved activity
US9796966B2 (en) 2011-12-08 2017-10-24 Roche Molecular Systems, Inc. DNA polymerases with improved activity
US9428782B2 (en) 2011-12-08 2016-08-30 Roche Molecular Systems, Inc. DNA polymerases with improved activity
US9951320B2 (en) 2011-12-08 2018-04-24 Roche Molecular Systems, Inc. DNA polymerases with improved activity
US10294462B2 (en) 2011-12-08 2019-05-21 Roche Molecular Systems, Inc. DNA polymerases with improved activity
US10487315B2 (en) 2011-12-08 2019-11-26 Roche Molecular Systems, Inc. DNA polymerases with improved activity
US9080156B2 (en) 2011-12-08 2015-07-14 Rocher Molecular Systems, Inc. DNA polymerases with improved activity
WO2017019617A1 (fr) * 2015-07-24 2017-02-02 Manel Camps Système pour la mutagenèse continue in vivo pour faciliter une évolution dirigée
US10760071B2 (en) 2015-07-24 2020-09-01 The Regents Of The University Of California System for continuous mutagenesis in vivo to facilitate directed evolution
CN108130318A (zh) * 2018-02-28 2018-06-08 深圳市草履虫生物科技有限公司 突变型Taq DNA聚合酶、免核酸提取直接PCR扩增的试剂盒及其应用
CN108130318B (zh) * 2018-02-28 2020-07-14 深圳市艾伟迪生物科技有限公司 突变型Taq DNA聚合酶、免核酸提取直接PCR扩增的试剂盒及其应用
CN108588050A (zh) * 2018-05-14 2018-09-28 北京艾克伦医疗科技有限公司 Dna聚合酶以及核酸检测方法和试剂盒

Also Published As

Publication number Publication date
CA2485203A1 (fr) 2003-12-11
JP2005528114A (ja) 2005-09-22
EP1504091A2 (fr) 2005-02-09
WO2003102213A3 (fr) 2004-06-17
EP1504091A4 (fr) 2006-04-26
AU2003237269A1 (en) 2003-12-19

Similar Documents

Publication Publication Date Title
US5780270A (en) Site-specific mutagenesis and mutant selection utilizing antibiotic-resistant markers encoding gene products having altered substrate specificity
JP4473573B2 (ja) 多部位突然変異誘発
Suzuki et al. Random mutagenesis of Thermus aquaticus DNA polymerase I: concordance of immutable sites in vivo with the crystal structure.
JP2023528484A (ja) Ｄｎａ生産のための細菌株
JP2007504817A (ja) ヌクレオチド類似体の改善された取り込みのための修飾ポリメラーゼ
US9777266B2 (en) Methods for efficient, expansive, user-defined DNA mutagenesis
Strauss et al. Role of proofreading and mismatch repair in maintaining the stability of nucleotide repeats in DNA
Seng Wong et al. Transversion‐enriched sequence saturation mutagenesis (SeSaM‐Tv+): A random mutagenesis method with consecutive nucleotide exchanges that complements the bias of error‐prone PCR
JP2016507252A (ja) 定方向進化のためのライブラリーの作製方法
EP1154017B1 (fr) Polymerase d'adn thermoastable modifiee de pyrococcus kodakaraensis
US20240167004A1 (en) Highly specific taq dna polymerase variant and use thereof in genome editing and gene mutation detection
WO2003102213A2 (fr) Mutants de polymerase i d'adn sujet a l'erreur et techniques de mutagenese aleatoire ciblee en culture continue utilisant ces mutants de polymerase i d'adn sujet a l'erreur
WO2021151085A2 (fr) Enzymes crispr-cas ayant une activité sur cible améliorée
CN113774077A (zh) 一种应用于结核分枝杆菌的单碱基基因编辑系统及方法
EP1390482A1 (fr) Compositions et procedes pour la mutagenese aleatoire d'acide nucleique
US20070184520A1 (en) Reduction of spontaneous mutation rates in cells
RU2312897C1 (ru) Рекомбинантная термостабильная формиатдегидрогеназа
EP1670914B1 (fr) Procédé pour la mutagenèse de saturation de séquence (sesam)
US9416359B2 (en) Method for constructing mutagenesis libraries in situ
Jin et al. Role of the double-strand origin cruciform in pT181 replication
US11787841B2 (en) Rationally-designed mutations to the thrA gene for enhanced lysine production in E. coli
US5731185A (en) Isolated DNA encoding the hphi restriction endonuclease and related methods for producing the same
US20090269803A1 (en) In Vivo Generation of Dna, Rna, Peptide, and Protein Libraries
JP2024501040A (ja) ヒスチジンによるフィードバック抑制が減少したａｔｐ－ｐｒｔ変異体およびこれを発現するヒスチジン生産菌株
US20060057627A1 (en) Selection scheme for enzymatic function

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2485203

Country of ref document: CA

Ref document number: 2003237269

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2003736735

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2004510449

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2003736735

Country of ref document: EP

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)